Streetbeat News

Analyst Ratings

ALLO

Allogene Therapeutics presented updated data from Phase 1 ALPHA/ALPHA2 trials of ALLO-501/501A for large B-cell lymphoma treatment, showing promising results. Analysts from William Blair and Canaccord Genuity see potential for first-in-class status and continued efficacy improvement.

Portfolio Pulse from Vandana Singh

June 16, 2023 | 6:02 pm

MRSN

Over the past 3 months, 4 analysts have published their opinion on Mersana Therapeutics (NASDAQ:MRSN) stock, with 3 bullish and 1 indifferent. The company has an average 12-month price target of $11.0, down 13.18% from the previous average of $12.67.

Portfolio Pulse from Benzinga Insights

June 16, 2023 | 6:02 pm

ARCC

Ares Capital (NASDAQ:ARCC) has received 2 bullish, 2 somewhat bullish, and 1 indifferent analyst rating in the last quarter, with an average price target of $19.7, implying an upside from the current price of $18.635. The average price target has decreased by 10.45% from the previous average of $22.00.

Portfolio Pulse from Benzinga Insights

June 16, 2023 | 6:02 pm

ORA

Over the past 3 months, 5 analysts have published their opinion on Ormat Technologies (NYSE:ORA) stock, with an average price target of $90.6, implying upside from the current price of $85.95. The current average represents a 1.52% decrease from the previous average price target of $92.00.

Portfolio Pulse from Benzinga Insights

June 16, 2023 | 6:01 pm

LADR

Over the past 3 months, 6 analysts have published their opinion on Ladder Cap (NYSE:LADR) stock, with an average price target of $11.25, representing an upside from the current price of $10.685. The current average is a 8.16% decrease from the previous average price target of $12.25.

Portfolio Pulse from Benzinga Insights

June 16, 2023 | 6:01 pm

XPEV

Analysts have provided indifferent ratings for XPeng (NYSE:XPEV) within the last quarter, with an average 12-month price target of $9.76, a decrease of 0.41% from the previous average price target of $9.80.

Portfolio Pulse from Benzinga Insights

June 16, 2023 | 6:00 pm

EQIX

BMO Capital Markets analyst Ari Klein raised the price target of Equinix Inc (NASDAQ:EQIX) to $870 from $800, maintaining an Outperform rating. Klein expects EQIX to raise its long-term revenue growth guidance and AFFO per share growth guidance at its upcoming investor day on June 21.

Portfolio Pulse from Lekha Gupta

June 16, 2023 | 5:55 pm

CLFD

Needham analyst Ryan Koontz reiterated a Buy rating on Clearfield, Inc. (NASDAQ:CLFD) and raised the price target to $60 from $50. The company is benefiting from a surge in rural broadband infrastructure investment and exploring growth opportunities in Europe. However, inventory overhang and labor shortages are headwinds for the company.

Portfolio Pulse from Nabaparna Bhattacharya

June 16, 2023 | 5:38 pm

NEX

NexTier Oilfield Solutions' stock is trading lower after Citigroup downgraded it from Buy to Neutral, but raised its price target from $9.5 to $9.75.

Portfolio Pulse from Benzinga Newsdesk

June 16, 2023 | 5:37 pm

ESTE

NOG

Earthstone Energy (ESTE) acquires Novo Oil & Gas Holdings for $1.5 billion, while Northern Oil & Gas (NOG) acquires a 33.33% stake in Novo assets for $500 million. Analyst Mike Scialla of Stephens & Co. reiterates an Overweight rating on ESTE and raises the price target to $21 from $18.

Portfolio Pulse from Nabaparna Bhattacharya

June 16, 2023 | 5:32 pm